Saturday 17 October 2026
Export BNGO’s income statement to Excel — free account
Bionano Genomics, Inc.
BNGO Healthcare Medical Instruments & Supplies
Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
1.25
0.12
−8.76%
Follow BNGO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.32 | 0.29 | 0.45 | 0.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.54) | (2.00) | (2.25) | (2.79) | |
P/B ratio |
0.18 | 0.19 | 0.34 | 0.41 | |
Price to Tangible BV |
0.21 | 0.21 | 0.37 | 0.44 | |
EV/Sales |
(0.17) | (0.12) | 0.20 | 0.67 | |
EV/EBITDA |
0.18 | 0.14 | 0.00 | 0.00 | |
EV/Operating CF |
0.27 | 0.21 | (0.30) | (0.99) | |
EV/FCF |
0.27 | 0.21 | (0.30) | (0.99) | |
Quick Ratio |
1.58 | 1.51 | 1.36 | 1.47 | |
Current Ratio |
2.12 | 1.98 | 1.84 | 2.48 | |
Net Debt/EBITDA |
4.47 | 4.07 | 3.70 | 1.40 | |
Debt/Assets |
4.42% | 4.73% | 5.34% | 7.24% | |
Debt/Equity |
0.07 | 0.08 | 0.09 | 0.11 | |
Asset Turnover |
0.35 | 0.38 | 0.40 | 0.49 | |
Operating CF/Net income |
0.70 | 0.53 | 0.69 | 0.63 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
38.60% | 40.61% | 46.94% | 36.57% | |
Selling, General and Administrative Expense of Revenue |
123.04% | 109.51% | 119.78% | 104.56% | |
Intangible Assets out of Total Assets |
0.07 | 0.06 | 0.05 | 0.04 | |
Share Based Compensation of Revenue |
12.77% | 11.65% | 10.02% | 11.87% | |
Graham Net Nets |
2.14 | 1.95 | 0.91 | 0.68 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(689.32%) | (311.11%) | (373.50%) | (267.26%) | |
Free Cash Flow Yield |
(205.71%) | (197.43%) | (151.03%) | (157.76%) | |
Revenue per Share |
1.38 | 1.46 | 0.61 | 0.71 | |
Operating CF per Share |
(1.11) | (0.77) | (0.52) | (0.40) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.11) | (0.77) | (0.52) | (0.40) | |
Cash per Share |
5.97 | 5.42 | 2.25 | 0.90 | |
Shareholders Equity per Share |
9.33 | 8.16 | 3.41 | 2.74 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
9.33 | 8.16 | 3.41 | 2.74 | |
Free Cash Flow |
(5.92) | (4.17) | (5.72) | (4.67) | |
Working Capital |
25.82 | 22.44 | 17.75 | 14.84 | |
Net Current Asset Value |
19.54 | 16.23 | 11.63 | 8.89 | |
EV/EBIT |
0.14 | 0.10 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.92 | 4.98 | 3.74 | 3.93 | |
Average Payables |
7.35 | 6.28 | 5.81 | 5.40 | |
Average Inventory |
10.69 | 8.28 | 7.43 | 6.92 | |
Average Assets |
83.21 | 75.13 | 71.61 | 61.80 | |
Average Common Equity |
49.33 | 39.90 | 42.83 | 38.49 |
Columns are period end dates